Clinical Trial Update: Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating two different schedules of dabrafenib and trametinib for stage III/IV or unresectable melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 | Status: ACTIVE_NOT_RECRUITING